Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: A Study of LY3451838 in Participants With Migraine [Phase 2]
A Phase 2 study of LY3451838 in participants with migraine has been completed with results posted.
-
CLINICAL_TRIALS research · 2023-11-27Clinical Trial Update: Mindfulness and Mechanisms of Pain Processing in Adults With Migraines [NA]
Clinical trial examining mindfulness and mechanisms of pain processing in adults with migraines has completed; results posted in 2023.
-
FDA approval · 2023-11-22FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Bionpharma Inc. under an ANDA.
-
FDA approval · 2023-11-17FDA Approved: TOPIRAMATE — Original Application (Dr. Reddys Laboratories Inc.)
FDA approves a generic version of Topiramate from Dr. Reddy's Laboratories Inc. through an Original Application (ANDA).
-
FDA approval · 2023-11-07FDA Approved: INDERAL LA — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Inderal LA (propranolol hydrochloride) by ANI Pharmaceuticals, Inc. The action confirms regulato…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: The Efficacy Of Lidocaine Infusion IN Chronic Unilateral Migraine Headache [Phase 2]
Phase 2 clinical trial update evaluating lidocaine infusion for chronic unilateral migraine headaches; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-10-24Clinical Trial Update: A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines. [Phase 3]
A Phase 3 clinical trial evaluating the effectiveness of PEA versus placebo for reducing pain severity and duration in migraines has complet…
-
FDA approval · 2023-10-23FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for divalproex sodium from Mylan Pharmaceuticals, indicating regulatory authorization for a generic …
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: Zolmitriptane as Prophylaxis for Chilhood Migraine [Phase 4]
A Phase 4 clinical trial update evaluating zolmitriptane as prophylaxis for childhood migraine is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: Melatonin for Adolescent Migraine Prevention Study [Phase 2]
Phase 2 clinical trial investigating melatonin for prevention of migraine in adolescents was terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache [Phase 4]
A Phase 4 study evaluated the efficacy and safety of erenumab (Aimovig) in adults with medication overuse headache; the trial has completed …
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) [Phase 3]
Phase 3 clinical trial update for MOVEMENT study evaluating a multimechanistic treatment for migraines; results posted after completion.
-
FDA approval · 2023-10-06FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for divalproex sodium from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-10-06FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for divalproex sodium from Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2023-10-02Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder [Phase 4]
Phase 4 trial evaluating fremanezumab for preventative treatment of migraine in patients with major depressive disorder has completed; resul…
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study [Phase 4]
A Phase 4 clinical trial studying onabotulinumtoxinA and galcanezumab for migraine has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: Transnasal Cooling for Migraine [NA]
Clinical trial update for transnasal cooling in migraine shows termination with results posted.
-
FDA approval · 2023-09-27FDA Approved: TOPIRAMATE — Original Application (Aurobindo Pharma Limited)
FDA approves the Original Application for Topiramate (generic) by Aurobindo Pharma Limited. Topiramate is used as an anticonvulsant for epil…
-
FDA approval · 2023-09-26FDA Approved: DIVALPROEX SODIUM — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for divalproex sodium, providing a generic option for this anticonvulsant/mood stabilizer…
-
FDA approval · 2023-09-12FDA Approved: DIHYDROERGOTAMINE MESYLATE NASAL — Supplemental Application (Cipla USA Inc.)
FDA approved Cipla's dihydroergotamine mesylate nasal product via a supplemental application, enabling its marketed use in the United States…
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: Maximizing Outcomes in Treating Acute Migraine [Phase 3]
A Phase 3 clinical trial update on acute migraine treatment completed with results posted in 2023.
-
FDA approval · 2023-08-18FDA Approved: DIHYDROERGOTAMINE MESYLATE — Original Application (Gland Pharma Limited)
FDA approved the original application for dihydroergotamine mesylate from Gland Pharma Limited. This represents the approval of a generic pr…
-
FDA approval · 2023-08-15FDA Approved: TOPIRAMATE — Original Application (Ajanta Pharma USA Inc.)
The FDA approved Ajanta Pharma USA Inc.'s generic Topiramate through an Original Application (ANDA 215663). This approval provides a generic…
-
FDA approval · 2023-08-07FDA Approved: TOPIRAMATE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Topiramate submitted by Zydus Lifesciences Limited.
-
FDA approval · 2023-07-31FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for divalproex sodium by Lupin Pharmaceuticals, Inc. under ANDA 078790.